The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.
Read More
Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.
Read More
Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.
Read More
Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction.
Read More
Antipsychotics remain a mainstay of delirium treatment despite significant concerns about their safety and efficacy. A pair of reports recently evaluated the evidence on their use in delirium.
Read More
After a rise of adverse psychiatric reports on montelukast (Singulair), an oral leukotriene inhibitor used for asthma and allergies, the FDA added a black box warning in March 2020 about mood and behavior changes including suicide.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
